Clinical trial · Interventional
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
NCT06758544CI-TRIAL-00093759recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single-center, single-arm, open investigator-initiated clinical study to evaluate the efficacy and safety of VRT106 in combination with chemotherapy in the treatment of resectable pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| Oncolytic virus VRT106 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- VRT106 combination with chemotherapy
- description
- VRT106 combination with chemotherapy
- interventionNames
- Drug: Oncolytic virus VRT106
- Drug: Chemotherapy
Primary outcomes (1)
- measure
- Safety and tolerability
- timeFrame
- About 3 years
- description
- Incidence rate of TRAE（Treatment-Related Adverse Event）
Secondary outcomes (1)
- measure
- Disease-free survival rate
- timeFrame
- About 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subject voluntarily agrees to participate in this study and signs an Institutional Review Board -approved informed consent prior to performing any of the Screening Visit procedures. 2. Males and females at 18-75 years of age, inclusive, at the Screening Visit. 3. Have a clinical diagnosis of pancreatic cancer. 4. An Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. 5. Expected survival time of≥6 months. 6. No serious hematologic and cardiac abnormalities of the liver, kidneys, or coagulation functions. Exclusion Criteria: 1. Prior treatment with other oncolytic virus or systemic therapy for pancreatic cancer. 2. Previous allogeneic hematopoietic stem cell transplantation or organ transplantation. 3. Immunocompromised patients. 4. Known alcohol or drug dependency. 5. Women who are pregnant or breastfeeding.
References
Publications (0)
Data not yet available
No reference posted for this study.